All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, How might the iberdomide safety profile be critical for its future applications?
How might the iberdomide safety profile be critical for its future applications?
Lonial discusses the safety profile of iberdomide (CC-220) in combination with other agents. He also mentions the promising safety profile as well as adverse events, such as myelosuppression.
Your opinion matters
ASCO 2019 | Phase I study of iberdomide (IBER) in relapsed/refractory multiple myeloma
The phase Ib/IIa results (NCT02773030) of iberdomide (IBER, CC 220) for the treatment of relapsed/refractory multiple myeloma (RRMM) presented at ASCO 2019.
ASCO 2019 | Phase Ib/IIa study of iberdomide, in combination with dexamethasone, in patients with RRMM
Our Co-Chair, Sagar Lonial, Winship Cancer Institute at Emory University, Atlanta, US discusses the highlights from the phase Ib/IIa study of...
Subscribe to get the best content related to multiple myeloma delivered to your inbox